Laboratory Considerations for Clinical Trials
Science:Life Sciences
Dr. Patrice Hugo, Chief Scientific Advisor at Q2 Solutions discusses the selection and use of biomarkers in Immuno-oncology trials and the importance of early engagement between sponsors and clinical trial partners.
We are seeing that too often, in early phase clinical trials, drug developers for immuno-oncology investigation of products are considering bio-markers as true CDx or companion diagnostics; when in fact, they aim at producing information at a later stage, evaluating the potential of these bio-markers to be of CDx. At times the confusion here is adding a lot of pressure to the clinical labs to validate the assays to a level of stringency that is not necessarily required at that early stage. It also adds to the cost and complexity of the study. For bio-markers that are not considered as companion diagnostics, one of the main problems is how the data is generated, and how it's going to be used by the sponsor to support their drug development.
Dr. Hugo explains the importance of the results generated from candidate companion diagnostic markers, the relationship with IVD manufacturers that are developing CDx and the global regulatory environment.
What is the Role of Digital Pathology in Clinical Trials
AI in Pathology: Advancements, Challenges, and the Road Ahead
Flow Cytometry as an IVD technology for Companion Diagnostics
Flexible Approaches for Biotech Companies in Clinical Trials
Risk Management for Biotech Companies in Clinical Trials
3 Things to Consider in Preparation for Your Biotech Testing or Trial
Hybrid assays: an interview with Barry Jones and Adriane Spytko
Managing Sample Data from Vendors
Automation within an ADME Laboratory
Bioanalytical Automation of Samples
Consent Tracking for Clinical Samples
Tracking Clinical Trial Samples
Avoiding Canceled Tests in Pediatric Samples
Covid Vaccine Testing
Hybrid Assays for Protein Bioanalysis
High Throughput ADME Testing
Liquid Biopsy Collection in Clinical Development Programs
An Next Generation Sequencing Approach to Influenza Vaccine Development
Standardization of Tumor Mutational Burden by Alignment to Reference Standards
Monitoring the Tumor Micro-environment with Flow Cytometry - Mark Edinger
Create your
podcast in
minutes
It is Free
Short Wave
Unexplainable
Stuff To Blow Your Mind
Breakthrough
The Science of Life with Dr. Raven Baxter